Name: Pancreatic Cancer, an Issue of Hematology/Oncology Clinics of North America, 1e: Volume 29-4 (The Clinics: Internal Medicine) (en Inglés)
Price: 1109.60 MXN
Availability: InStock
Author: Wolpin Md Brian M.
ISBN: 9780323393362

Envío gratis

portada Pancreatic Cancer, an Issue of Hematology/Oncology Clinics of North America, 1e: Volume 29-4 (The Clinics: Internal Medicine) (en Inglés)

Formato

Libro Físico

Editorial

Mosby,

Autor

Wolpin Md Brian M.

Idioma

Inglés

Encuadernación

Tapa Dura

ISBN13

9780323393362

Pancreatic Cancer, an Issue of Hematology/Oncology Clinics of North America, 1e: Volume 29-4 (The Clinics: Internal Medicine) (en Inglés)

Wolpin Md Brian M. (Autor) · Mosby, · Tapa Dura

Libro Nuevo

$ 1,109.60

$ 2,219.21

Ahorras: $ 1,109.60

50% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 12 de Junio y el Lunes 24 de Junio.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Pancreatic Cancer, an Issue of Hematology/Oncology Clinics of North America, 1e: Volume 29-4 (The Clinics: Internal Medicine) (en Inglés)"

This issue of Hematology/Oncology Clinics of North America is devoted to Pancreatic Cancer. Guest Editor Brian Wolpin, MD has assembled a group of expert authors to review the following topics: Biology and genetics of pancreatic adenocarcinoma; Mouse models of pancreatic adenocarcinoma; Epidemiology and inherited predisposition for sporadic pancreatic adenocarcinoma; Familial pancreatic adenocarcinoma; Imaging and endoscopic approaches to pancreatic cancer; Diagnosis and management of pancreatic cystic neoplasms; Surgical management of pancreatic cancer; Peri-operative therapy for surgically resectable pancreatic adenocarcinoma; Diagnosis and management of borderline resectable pancreatic adenocarcinoma; Treatment approaches to locally advanced pancreatic adenocarcinoma; Therapeutic approaches for metastatic pancreatic adenocarcinoma; Supportive and end-of-life care for patients with pancreatic adenocarcinoma; and Novel therapeutics for pancreatic adenocarcinoma.